Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, reported first-quarter 2026 results on April 30, demonstrating a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential growth from Q4 2025. The company attributed the growth to new account activations and deeper utilization within existing sites, signaling increasing integration of its Nociscan platform into clinical workflows for chronic low back pain diagnosis.
The Nociscan platform uses magnetic resonance spectroscopy, biomarkers, and proprietary augmented intelligence algorithms to help physicians identify the location of discogenic pain. According to the company, approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies like Nociscan that provide objective, data-driven evaluation.
Key drivers of growth include reimbursement progress in the U.K., where Nociscan is now reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers. The company also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage with payers through its Nociscan Reimbursement Program to establish coverage pathways.
Clinical milestones are advancing, with the CLARITY randomized trial expected to have a preliminary internal readout in the second half of 2026 and public disclosure of early interim results anticipated in late 2026. The company also reported seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions by commercial insurers.
Aclarion strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide. Financially, the company reported $19.0 million in cash as of March 31, 2026, with no debt and a clean capital structure. A $2.5 million share repurchase program was announced, and management believes existing cash resources are sufficient to fund operations into the second half of 2027.
“Q1 represents a clear inflection for Aclarion,” said Brent Ness, CEO. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”
For more information, visit the company's newsroom at https://tinyurl.com/aconnewsroom.
